Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Last trade $48.67
Day change +$0.67 (+1.40%)
Day range $44.50 – $49.68
Volume 328,737
Market cap $2.28B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$2.28B
Price / earnings
14.67×
Price / book
1.17×
Price / sales
1.95×
EV / sales
3.71×
EV / EBITDA
12.54×

Profitability

Earnings per share
$3.27
Return on assets
3.28%
Return on equity
7.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.08×
Current ratio
2.92×
Quick ratio
1.86×
Cash ratio
0.28×

Cash flow

Price / cash flow
9.9×
Price / free cash flow
10.62×
Free cash flow
$214.22M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PBH, quarterly periods
Line itemQ2 FY2027 Sep 30, 2026Q1 FY2027 Jun 30, 2026Q4 FY2026 Mar 31, 2026Q3 FY2026 Dec 31, 2025Q2 FY2026 Sep 30, 2025Q1 FY2026 Jun 30, 2025Q4 FY2025 Mar 31, 2025Q3 FY2025 Dec 31, 2024
Revenue$336.31M$265.71M$281.62M$283.44M$274.11M$249.53M$296.52M$290.32M
Cost of revenue$163.77M$129.52M$135.32M$126.08M$122.54M$109.2M$126.51M$129.27M
Gross profit$172.54M$136.19M$146.3M$157.37M$151.58M$140.33M$170.01M$161.05M
Selling, general and administrative$83.12M$77.97M$65.37M$69.73M$66.74M$63.39M$64.05M$64.13M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$91.83M$83.67M$70.81M$74.88M$71.91M$68.58M$81.58M$69.09M
Operating income$80.71M$52.52M$75.49M$82.49M$79.67M$71.76M$88.43M$91.96M
Interest expense-$30.03M-$13.95M$30.91M-$10.67M-$10.04M-$10.2M$36.87M-$11.46M
Income before taxes$47.45M$38.54M$64.77M$61.81M$69.13M$61.78M$73.96M$80.15M
Income taxes$22.16M$9.36M$10.84M$15.12M$26.92M$14.31M$23.83M$19.12M
Net income$25.3M$29.18M$53.93M$46.7M$42.21M$47.47M$50.13M$61.03M
Net income attributable to common shareholders$25.3M$29.18M$53.93M$46.7M$42.21M$47.47M$50.13M$61.03M
EBITDA$109.88M$61.27M$83.84M$90.08M$87.33M$79.42M$108.15M$98.83M
Basic earnings per share$0.53$0.61$1.14$0.98$0.86$0.96$1.01$1.23
Diluted earnings per share$0.53$0.61$1.13$0.97$0.86$0.95$1.00$1.22

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Prestige Consumer Healthcare (PBH) Beats Q2 Earnings and Revenue Estimates

Prestige Consumer Healthcare reported Q2 earnings of $1.13 per share, beating consensus estimates of $1.06, with revenues of $336.31 million exceeding expectations by 2.31%. Despite the earnings beat, the stock has underperformed the market by 13.6% year-to-date. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

Zacks Investment Research

biote Corp. (BTMD) Tops Q3 Earnings Estimates

biote Corp. (BTMD) reported quarterly earnings of $0.01 per share, beating the consensus estimate of -$0.05 loss by 120%, but missed revenue expectations at $43.33 million versus the estimated $44.13 million. The stock has declined 56.9% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Medical-Products industry ranks in the bottom 37% of Zacks industries.

Zacks Investment Research

GE HealthCare Technologies (GEHC) Q3 Earnings and Revenues Beat Estimates

GE HealthCare Technologies reported Q3 2026 earnings of $1.34 per share, beating consensus estimates of $1.21, with revenues of $5.51 billion exceeding expectations by 2.87%. However, the stock has underperformed the market, declining 13.3% year-to-date versus the S&P 500's 12.8% gain. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now?

Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average.

Zacks Investment Research

Best Value Stocks to Buy for October 1st

Recent economic data shows PCE inflation came in softer than expected while Q2 GDP exceeded expectations. The market is now focused on the upcoming Friday employment report. Two stocks highlighted as strong buys are BP, an integrated energy company with a Zacks Rank #1 and improving earnings estimates, and Prestige Consumer Healthcare, also with a Zacks Rank #1 rating.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Dec 27, 2013$0.3125Jan 15, 2014unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.